Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2023 Earnings Call Transcript March 19, 2024
Corvus Pharmaceuticals, Inc. reports earnings inline with expectations. Reported EPS is $-0.14 EPS, expectations were $-0.14. CRVS isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).
Operator: Good afternoon everyone. Thank you for standing by and welcome to the Corvus Pharmaceuticals’ Fourth Quarter and Full Year 2023 Business Update and...
